What Onxeo does

Onxeo, now commercially operating as Valerio Therapeutics, is a France-domiciled, publicly traded clinical-stage biotechnology company focused on precision-guided therapeutics for oncology and other complex diseases with high unmet medical need. The company is built around a proprietary V-Body platform based on two fully synthetic single-domain antibody (sdAb) libraries — one derived from a human VH and one from a fully humanized VHH — yielding ultra-small antibodies of approximately 15 kDa that are engineered for deep tissue penetration and highly precise therapeutic delivery. The V-Body platform is integrated with a proprietary chemistry stack that provides novel linker and payload technologies for drug-conjugate development, and target identification is supported by advanced predictive models and antibody engineering aimed at high specificity and affinity.

Commercially, the company does not sell products directly. Its business model is partnership-driven: candidates are advanced from preclinical research through clinical proof-of-concept in indications with limited treatment options, and then monetized through co-development arrangements, out-licensing deals, and R&D collaborations with other biopharmaceutical companies. Customers are therefore enterprise biopharma partners rather than end patients, and pricing/contract terms are not publicly disclosed. The company employs 11-50 people and is listed on Euronext Growth Paris under ticker ALONX, having previously operated under the Onxeo name.

Between October 2025 and mid-2026 the company executed a dense strategic transformation: a capital increase with cancellation of preferential subscription rights (October 2025), completion of a merger with its subsidiary Valour Bio (December 2025), appointment of a new CEO (Gilles Besin, June 2026), relocation of headquarters and laboratories to The Hive by Kadans facility in Villejuif (March 2026), and the May 2026 launch of InVimmune, a wholly-owned subsidiary focused on differentiated in vivo cell therapy. It also signed a binding term-sheet for an exclusive license collaboration with a seed-stage biotech in May 2026. The strategic posture is best characterized as a platform company rebuilding its operating model around the V-Body and chemistry stacks while extending into adjacent modalities via spin-out vehicles.

Name

Onxeo

Legal name

Valerio Therapeutics

Website

https://onxeo.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Valerio Therapeutics (formerly Onxeo) is a French clinical-stage biotechnology company developing precision-guided therapeutics for complex diseases using its proprietary synthetic single-domain antibody V-Body platform and integrated chemistry stack, monetizing candidates via out-licensing and R&D partnerships with other biopharmaceutical companies.

Ownership category

akta.pro rank

Product category

Precision-Guided Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Precision-guided therapeutics
• Single-domain antibody platform
• Drug conjugate development
• Oncology biopharmaceuticals
• Antibody-drug conjugates

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Strategic partnerships and licensing: Valerio Therapeutics advances therapeutic candidates to key development milestones before forging strategic partnerships. Revenue is generated through co-development arrangements, out-licensing deals, and R&D collaborations to maximize the potential of innovations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Valerio Therapeutics (formerly Onxeo) develops precision-guided therapeutics through two integrated proprietary platforms: the V-Body Platform, based on ultra-small (~15 kDa) fully synthetic single-domain antibodies enabling deep tissue penetration and precise therapeutic delivery, and the Fully Integrated Chemistry Platform for drug conjugate development. The company advances candidates from preclinical research to clinical proof of concept in indications with high unmet medical need, then commercializes via strategic partnerships, co-development, and out-licensing.

Product overview

Valerio Therapeutics (formerly Onxeo) is a biotechnology company pioneering next-generation precision-guided therapeutics. The company operates two integrated proprietary platforms: the V-Body Platform (based on ultra-small single-domain antibodies of ~15 kDa for deep tissue penetration and precise therapeutic delivery) and the Fully Integrated Chemistry Platform (leveraging cutting-edge linker and payload technologies). These platforms work together to enable drug conjugate development targeting complex and underserved diseases. The company also launched InVimmune as a new subsidiary focused on in vivo cell therapy approaches. Valerio Therapeutics advances therapeutic candidates through preclinical research to clinical proof of concept in indications with high unmet medical needs, with a business model focused on strategic partnerships, co-development, and out-licensing.

Differentiator

Problem solved

Functional benefit

Products and services

• V-Body Platform Proprietary technology platform based on two fully synthetic single-domain antibody (sdAb) libraries derived from human VH and fully humanized VHH; the ultra-small (~15 kDa) sdAb format enables deep tissue penetration and highly precise therapeutic delivery for superior efficacy and target engagement in complex and underserved diseases.
• Fully Integrated Chemistry Platform Proprietary chemistry platform integrated with the V-Body platform for drug conjugate development, leveraging cutting-edge linker and payload technologies to enable precise and efficient targeted delivery of therapeutics.
• InVimmune Newly launched wholly owned subsidiary company dedicated to developing differentiated in vivo cell therapy approaches, expanding the therapeutic pipeline beyond traditional conjugate therapeutics.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Seed-stage biotech companycoreStrategic or Co-development Partner · 18 May 2026Valerio Therapeutics announced a binding term-sheet for collaboration and exclusive license with a seed-stage biotech company on May 18, 2026. This partnership represents a strategic collaboration to advance therapeutic development through exclusive licensing arrangements.
• InVimmunecoreStrategic or Co-development Partner · 4 May 2026Valerio Therapeutics announced the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches on May 4, 2026. This represents the company's expansion into novel therapeutic modalities through strategic venture creation.
• Valour BiocoreStrategic or Co-development Partner · 12 December 2025Completion of merger between Valerio Therapeutics and its subsidiary Valour Bio on December 12, 2025, following the proposed merger announced on October 31, 2025. This consolidation streamlines operations and strengthens the company's therapeutic development capabilities.

Scale indicators1 record

Recent moves8 records

Expansion highlights5 records

Direct peers

• Argenx: Commercial-stage biotech built on llama-derived VHH single-domain antibodies; the closest comparable to Valerio's V-Body sdAb platform, with multiple approved and late-stage autoimmune programs.
• Molecular Partners: Develops DARPins and other small designed binding proteins for oncology; comparable to Valerio's use of ultra-small, fully synthetic single-domain scaffolds for targeted therapeutics.
• Harbour BioMed: Operates a single-domain antibody (HBM7008 and others) platform spanning immuno-oncology and immunology; directly comparable in using sdAb-based therapeutics.
• Genmab: Antibody platform company (Duobody, Hexabody) with multiple approved and partnered oncology assets; comparable partner-driven business model and focus on next-generation antibody engineering.
• Pyxis Oncology: Clinical-stage developer of antibody-drug conjugates and immunotherapies for difficult-to-treat tumors; comparable ADC pipeline and oncology focus.

Emerging players

• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs); comparable as a small-cap ADC developer with platform technology.
• Cellectis: Clinical-stage gene and cell therapy company working on allogeneic and in vivo cell therapy approaches; relevant peer for Valerio's newly launched InVimmune subsidiary.

Broad incumbents

• ImmunoGen (AbbVie): Pioneer in ADC technology (now part of AbbVie following the 2024 acquisition); broader incumbent with approved ADCs and an established payload/linker franchise.
• Daiichi Sankyo: Co-developer of Enhertu and Datroway with AstraZeneca; large incumbent in the ADC space that Valerio's chemistry platform ultimately competes with or partners alongside.
• Sanofi (Ablynx): Acquired Ablynx, the originator of Nanobody/VHH therapeutics; the established large-pharma owner of the most clinically validated sdAb franchise (e.g., Cablivi).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/onxeo_
• LinkedInlinkedin.com/company/valerio-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onxeo